Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Cellectis S.A.NASDAQ: CLLS

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $4.83M (cash outflow) rose 18.0% year over year, ahead of the -123.8% change in trailing-twelve-month financing cash flow. Sequentially, it rose 19.8% from the prior quarter.

Context

  • Financing cash flow amounted to 22.2% of revenue in FY2025, down 194.2 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.0% holds above the trailing-twelve-month pace of -123.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.83M+19.8% QoQ
Last fiscal yearDec 2025
-$16.2M-118.0% YoY
LTMMar 2026
-$17.39M-123.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.0%——
1 year-118.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(16.2M) USD
Year-over-year change
-118.0%

Financing Cash Flow vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -123.8% is the lowest of 9, against a peer median of +77.9%.
  • Financing cash flow amounts to 25.5% of revenue for CLLS, versus a peer median of 19.1%.
CLLS Competitors
Financing Cash Flow for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DBVTDBV Technologies S.A.LTM Mar 2026$365.04M USD+52499.0%+12.5%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$173.2M USD+64727.2%-4.7%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$165.89M USD+1517.0%+11.1%—
KRROKorro Bio, Inc.LTM Mar 2026$88.73M USD+27.9%+236.4%2309.3%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$45.77M USD—-22.1%—
CLLSCellectis S.A.LTM Mar 2026$17.39M USD-123.8%—25.5%
AMRNAmarin Corporation plcLTM Mar 2026$2.59M USD+127.8%+75.3%1.2%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.02M CHF-9.0%-10.2%28.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$191.89K USD-76.4%-2.7%—
MREOMereo BioPharma Group plcLTM Mar 2026$95.27K USD-100.2%+17.8%19.1%
SLNSilence Therapeutics plcLTM Mar 2026$911.01 USD—-93.4%0.1%
Peer median (excluding CLLS) —+77.9%+4.2%19.1%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(96.75M)(98.69M)(116.84M)(36.7M)(67.8M)
Depreciation & Amortization14.16M18.44M18.52M19.84M20.12M
Deferred Income Tax087K371K00
Stock-Based Compensation11.49M6.04M5.23M00
Change in Working Capital(12.3M)(5.72M)(3.99M)53.57M(41.72M)
Accounts Receivables(12.44M)(8.99M)2.25M(6.72M)(4.44M)
Inventory215K0000
Accounts Payables177K3.25M(6.31M)2.05M(3.27M)
Other Working Capital(252K)23K67K58.24M(34.01M)
Other Non-Cash Items(21.17M)(7.6M)71.95M(14.61M)49.26M
Operating Cash Flow(104.56M)(87.44M)(24.75M)22.1M(40.14M)
Capital Expenditures(18.56M)(2.44M)(1.07M)(2.58M)(2.37M)
Acquisitions (Net)00000
Purchases of Investments(143K)00(162.48M)(160.27M)
Sales of Investments15M126K063.69M134.24M
Other Investing Activities10.97M(456K)(14.44M)00
Investing Cash Flow7.28M(2.76M)(15.51M)(102.63M)(29.58M)
Debt Repayment(10.64M)(6.6M)24.56M18.17M(5.4M)
Common Stock Issued44.64M067.94M82.68M44.14K
Common Stock Repurchased0(569K)000
Dividends Paid00000
Other Financing Activities13.53M8.32M(9.64M)(11.04M)(10.85M)
Financing Cash Flow47.53M1.15M82.87M89.8M(16.2M)
Effect of Forex Changes(5.75M)(3.36M)884K(2.73M)6.24M
Net Change in Cash(55.51M)(92.42M)43.49M6.54M(79.67M)
Free Cash Flow(123.12M)(89.89M)(25.82M)19.52M(42.5M)

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.